Frontiers in neuroscience

Key research topics and trends on GLP-1 receptor drugs for treating Parkinson's disease

Updated

Abstract

Glucagon-like peptide-1 receptor agonists may exert neuroprotective effects relevant to Parkinson's disease.

  • These compounds can cross the blood-brain barrier to varying extents.
  • They demonstrate anti-inflammatory, antioxidant, and insulin-sensitizing actions.
  • GLP-1 receptor agonists may reduce pathological protein aggregation.
  • They are associated with the regulation of mitochondrial function.
  • These agents could enhance autophagy, indicating their potential therapeutic role in Parkinson's disease.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free